Given the observation that TransCon TLR7/8 Agonist monotherapy induced activation of both innate (NK) and adaptive (CD8+) cytolytic cell types, we hypothesized that it could also potentiate anti-tumor efficacy when combined with systemic immunotherapy. Here, TLR7 is linked to neoplasm.